NCPA to recognize medication adherence best practices with two new annual awards
ALEXANDRIA, Va. — The National Community Pharmacists Association on Monday announced the establishment of two awards that will be presented annually, beginning in 2012.
The NCPA said the Outstanding Adherence Practitioner award will recognize a community pharmacist who demonstrates a commitment to improving medication adherence and improving patient outcomes in a community pharmacy setting; while the Outstanding Adherence Educator award will recognize a pharmacy educator who makes a significant contribution to the education of pharmacy students in the area of medication adherence.
“Community pharmacists provide outstanding levels of patient care services related to improving medication adherence, while the profession’s educators ensure the next generation of pharmacists are properly trained practitioners in this invaluable service,” NCPA president Lonny Wilson said. “In recognition of these unsung efforts, NCPA is establishing these awards to create broad awareness of these best practices and promote further adoption of medication adherence programs among community pharmacists—present and future.”
According to the New England Healthcare Institute, as much as $290 billion a year is wasted on the improper use of medication.
Nominees for the Outstanding Adherence Practitioner award will be judged on:
Demonstration of a continuous commitment to patient adherence services;
Implementation of coordinated adherence services involving other healthcare professionals;
Documentation of increased patient medication adherence; and
Promotion of availability and value of pharmacy-based adherence services.
Nominees for the Outstanding Adherence Educator award will be judged on:
Development of innovative course content or teaching tools on medication adherence;
Integration of active learning techniques on medication adherence throughout the PharmD curriculum and experiential education;
Provision of regular feedback, encouragement, and support to students who participate in medication adherence-related activities; and
Development of unique teaching strategies to improve medication adherence in pharmacy practice.
The awards are part of NCPA’s commitment to advancing adherence as a core competency of the pharmacy profession by 2015. Nomination forms for both awards will be available on the NCPA website on March 1, 2012, and applications will be accepted through July 31.
The winners will be announced at next year’s 114th Annual NCPA Annual Convention and Trade Exposition in San Diego.
Sagent Q3 net revenue jumps 94%
SCHAUMBURG, Ill. — Third-quarter net revenue for Sagent Pharmaceuticals jumped 94% to $41.3 million, thanks to several new product launches during the period.
Gross profit for the quarter ended Sept. 30 was $6.9 million, or 16.8% of net revenues, compared with $2.7 million, or 12.9% of net revenues, in the year-ago period.
"I am very pleased with the growth we achieved during the quarter, nearly doubling our gross margin percentage from the second quarter," Sagent founder, board chairman and CEO Jeffrey Yordon said. "We have seen strong demand for our new product launches, especially levofloxacin, where we were the first company to launch and gemcitabine. In addition, we have been able to help alleviate market shortages through the launches of vecuronium and paclitaxel. We expect to continue our revenue and gross margin momentum in the fourth quarter, while focusing on the launch of 40 additional products, which are represented by 75 [abbreviated new drug applications] that have been recently approved or are pending approval by the [Food and Drug Administration]."
FDA approves J&J’s Xarelto for stroke prevention
SILVER SPRING, Md. — The Food and Drug Administration has approved a drug made by Johnson & Johnson for preventing stroke in patients with abnormal heart rhythm, the agency said.
The agency announced Friday the approval of Xarelto (rivaroxaban), an anti-clotting made by J&J subsidiary Janssen Pharmaceuticals, in patients with non-valvular atrial fibrillation. The FDA approved the drug in the 10-mg strength in July for deep-vein thrombosis in patients receiving knee and hip replacement surgery. The latest approval includes 15-mg and 20-mg strengths.
Atrial fibrillation is one of the most common types of abnormal heart rhythm and affects more than 2 million people. The condition causes irregular and poorly coordinated beating of the heart’s two upper chambers, which leads to pooling and clotting of blood.
"Atrial fibrillation can lead to the formation of blood clots, which can travel to the brain, blocking blood flow and causing a disabling stroke," FDA Division of Cardiovascular and Renal Products director Normal Stockbridge said. "This approval gives doctors and patients another treatment option for a condition that must be managed carefully."